Evidence map›Paper›PMID 39672901›Full record

ArticleThe Journal of antibiotics2025

Differential gene expression analysis shows that cephalosporin resistance is intrinsic to Clostridioides difficile strain 630.

Lara A Turello, Amber Consul, Christopher Yip, Shirley Shen, Cale Seymour, Corey Geurink, Israel Alvarado, Ernesto Abel-Santos

Abstract read
In one paragraph

Article in The Journal of antibiotics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Peptidoglycan LD-Transpeptidases.Antibiotics (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lara A TurelloDepartment of Chemistry and Biochemistry, University of Nevada, Las Vegas, Las Vegas, NV, USA.ORCID 0000-0001-7170-0125
Amber ConsulDepartment of Chemistry and Biochemistry, University of Nevada, Las Vegas, Las Vegas, NV, USA.
Christopher YipDepartment of Chemistry and Biochemistry, University of Nevada, Las Vegas, Las Vegas, NV, USA.
Shirley ShenNevada Institute of Personalized Medicine, University of Nevada, Las Vegas, Las Vegas, NV, 89154-4004, USA.
Cale SeymourDepartment of Chemistry and Biochemistry, University of Nevada, Las Vegas, Las Vegas, NV, USA.
Corey GeurinkNevada Institute of Personalized Medicine, University of Nevada, Las Vegas, Las Vegas, NV, 89154-4004, USA.
Israel AlvaradoDepartment of Chemistry and Biochemistry, University of Nevada, Las Vegas, Las Vegas, NV, USA.
Ernesto Abel-SantosDepartment of Chemistry and Biochemistry, University of Nevada, Las Vegas, Las Vegas, NV, USA. ernesto.abelsantos@unlv.edu.ORCID 0000-0002-2628-9493

Funding

Using bile salt metabolism to modulate CDI prophylaxisR01AI109139 · NIAID · UNIVERSITY OF NEVADA LAS VEGAS · PI Ernesto V Abel-Santos · 2015 to 2026
$5.4M
Effects of estrus cycle stages on murine CDI severityR16AI175022 · NIAID · UNIVERSITY OF NEVADA LAS VEGAS · PI Ernesto V Abel-Santos · 2023 to 2026
$584k
NIAID NIH HHS R01 AI109139NIAID NIH HHS R16 AI175022U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI109139U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R16AI175022U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) P20GM12132
6 · The paper itself

Abstract

Clostridioides difficile infection (CDI) is the most common nosocomial infection in the US. CDI has become a growing concern due to C. difficile's resistance to several antibiotics, including cephalosporins. Furthermore, patients administered cephalosporins are at higher risk of contracting CDI. Cephalosporins are β-lactam antibiotics, which prevent bacterial cell wall synthesis by inhibiting penicillin-binding proteins (PBPs). β-lactam-resistant bacteria evade these antibiotics by producing β-lactamases or by harboring low-affinity PBPs. A genomic analysis of C. difficile strain 630 identified 31 putative β-lactam resistance genes. Upon cefoxitin exposure, few C. difficile strain 630 putative antibiotic-resistant genes were overexpressed. Most notably, the β-lactamase blaCDD gene was upregulated approximately 600-fold, as previously reported. Deletion of the blaCDD locus did not change in cephalosporin susceptibility. Deletion of the second most upregulated gene, the PBP vanY, was also ineffective at decreasing cephalosporin resistance. Cefoxitin exposure of the C. difficile strain 630ΔblaCDD mutant did not increase upregulation of other putative antibiotic resistance genes compared to wildtype C. difficile strain 630. Transcriptomic analyses of wildtype C. difficile strain 630 exposed to cephradine, cefoxitin, ceftazidime, or cefepime revealed the shared upregulation of a putative heterodimeric ABC transporter encoded by loci CD630_04590 (ABC transporter ATP-binding protein) and CD630_04600 (ABC transporter permease). These genes are genomically located directly downstream of blaCDD (CD630_04580). The deletion mutant CD630_04600 remained resistant to a number of antibiotics. Thus, even though blaCDD, CD630_04590, and CD630_04600 are all upregulated when exposed to cephalosporins, they do not seem to be involved in antibiotic resistance in C. difficile strain 630.

Indexed as

Anti-Bacterial AgentsCephalosporin ResistanceClostridioides difficileMicrobial Sensitivity TestsBacterial Proteinsbeta-LactamasesCefoxitinCephalosporinsClostridium InfectionsGene Expression ProfilingGene Expression Regulation, BacterialHumansAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesblaCDD protein, Clostridium difficileCefoxitinCephalosporins

Identifiers

PMID39672901
PMCPMC12021185

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.